Asaria et al. reported a significant reduction in the incidence of postoperative pro-liferative vitreoretinopathy in patients receiving 5-fluorouracil and low-molecular-weight heparin therapy and in the reoperation rate resulting from proliferative vitreoretinopathy (100). However, Charteris et al. reported that a combined perioperative infusion of 5-fluorouracil and low-molecular-weight heparin did not significantly increase the success rate of vitreoretinal surgery for established prolif-erative vitreoretinopathy (101). Furthermore, Williams et al. revealed no significant reduction in the reproliferation rate in proliferative vitreoretinopathy patients prospectively receiving high-molecular-weight heparin and dexametha-sone (102).
On the other hand, the maximum tolerated dose of enoxaparin, a low-molecular-weight heparin, during vitrectomy for rhegmatogenous retinal detachment with proliferative vitreoretinopathy and severe diabetic retinopathy was determined (103). The study was able to achieve the 6.0 IU/ml maximum dose in the infusion fluid, and enoxaparin dose escalation did not result in a dose-dependent increase in acute side effects.
Was this article helpful?